Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:NVO 15 August 2025 - 9 February 2026

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk forecast 2026 adjusted sales and operating profit will fall 5%–13% at constant exchange rates, citing pricing pressure and competition. U.S.-listed shares dropped about 12% after the outlook. The company reported 2025 sales up 10% to 309.1 billion Danish crowns and operating profit up 6%. Early U.S. uptake of its Wegovy pill was noted, but patent expiries and lower realized prices remain concerns.
3 February 2026
·
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B shares closed up 1.17% at 401.35 crowns in Copenhagen, lifted by strong early U.S. demand for its new Wegovy pill. The company faces a new U.S. lawsuit alleging a “pay-for-delay” scheme for Victoza. Over 18,000 Wegovy pill prescriptions were reported in the U.S. since its Jan. 5 launch. Indian regulators approved local firms to make generic semaglutide ahead of the 2026 patent expiry.
24 January 2026
··
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly shares closed Friday at $1,038.40, up 0.5% after trading between $1,019 and $1,049.83. Investors are watching for FDA decisions on Lilly’s obesity pill and tracking early prescription data as Novo Nordisk’s Wegovy pill posts strong initial sales. U.S. markets will be closed Monday, reopening Tuesday. Lilly’s next earnings call is scheduled for February 4.
18 January 2026
··
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon shares rose 0.4% after hours to $247.33 following news that Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill at $25 per month for insured customers and $149 for cash-pay. The pill, approved by the FDA in December, will be shipped to all 50 states. Investors await Amazon’s Q4 results on Feb. 5 and a key EU digital proposal on Jan. 20.
9 January 2026
····
Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management, marking the first U.S. approval of an oral GLP‑1 for obesity. The decision sent biotech shares higher and intensified competition in the obesity drug market. U.S. markets were closed for Christmas. Novo Nordisk plans a U.S. launch in early January 2026.
25 December 2025
·
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk’s Copenhagen shares are down nearly 50% in 2025, heading for their worst year on record. U.S. ADRs trade near $49 after a recent rebound. SEB now forecasts organic sales will fall in 2026, citing U.S. price cuts and pressure on Ozempic. Seeking Alpha downgraded the stock, pointing to structural challenges and slowing revenue growth.
11 December 2025
··
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk shares rose about 3–4% to $48 in New York trading on December 10 after months of steep losses. The move followed an Argus downgrade to Hold, citing GLP-1 market-share erosion and underwhelming trial results. Novo has submitted a higher-dose Wegovy application to the FDA. Shares remain down nearly 59% over the past year.
10 December 2025
··
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk shares plunged about 9% in Copenhagen to their lowest since July 2021 after phase 3 Alzheimer’s trials for semaglutide failed to meet the primary endpoint. The NVO ADR dropped to around $43.1 in U.S. pre-market trading, down nearly 10%. Year-to-date, the stock is off more than 50%. The company will present top-line trial data on December 3.
24 November 2025
··
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin surged past $125,000 to a record high as investors poured in. Elon Musk’s xAI and OpenAI filed lawsuits against each other, with OpenAI calling Musk’s claims “harassment.” Tesla teased an Oct. 7 event for a cheaper electric car. Firefly Aerospace agreed to buy defense firm SciTec for $855 million to expand military space work.
6 October 2025
··········
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
15 August 2025
···
Go toTop